Rafael (RFL)
Develops Trappsol Cyclo while holding healthcare, infusion-technology, and real-estate interests.
$2.06
vs last close+0.06 (+3.00%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Jul 2023 | Q1 FY24Oct 2023 | Q2 FY24Jan 2024 | Q3 FY24Apr 2024 | Q4 FY24Jul 2024 | Q1 FY25Oct 2024 | Q2 FY25Jan 2025 | Q3 FY25Apr 2025 | Q4 FY25Jul 2025 | Q1 FY26Oct 2025 | Q2 FY26Jan 2026 | Q3 FY26Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 3 | 3 | 93 | 4 | 4 | 7 | 6 | 13 | 10 | 7 | 7 | |
| Research & development | 1 | 0 | 1 | 91 | 2 | 1 | 1 | 3 | 8 | 7 | 5 | 5 |
| 1 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 5 | 3 | 2 | 2 | |
| General & administrative | 1 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 5 | 3 | 2 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −3 | −2 | −3 | −93 | −4 | −4 | −7 | −6 | −13 | −10 | −7 | −7 |
| 4 | −1 | 9 | 28 | −1 | −5 | 1 | −1 | 1 | 0 | 0 | 4 | |
| Interest income | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −4 | 1 | −9 | −28 | 1 | 5 | −1 | 0 | −1 | −1 | −1 | −4 |
| Income before tax | 1 | −4 | 6 | −65 | −5 | −9 | −5 | −6 | −12 | −10 | −6 | −3 |
| Income tax expense | 0 | 0 | 0 | −3 | 0 | 0 | 0 | −2 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | −4 | 6 | −62 | −5 | −9 | −5 | −4 | −12 | −10 | −6 | −3 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 1 | −4 | 6 | −32 | −4 | −9 | −5 | −5 | −12 | −10 | −6 | −4 |
| EPS, basic | $0.05 | −$0.15 | $0.26 | −$1.36 | −$0.19 | −$0.37 | −$0.19 | −$0.19 | −$0.28 | −$0.19 | −$0.13 | −$0.08 |
| EPS, diluted | $0.05 | −$0.15 | $0.26 | −$1.36 | −$0.19 | −$0.37 | −$0.19 | −$0.19 | −$0.28 | −$0.19 | −$0.13 | −$0.08 |
| Weighted average shares, basic | 22 | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 43 | 51 | 51 | 51 |
| Weighted average shares, diluted | 22 | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 43 | 51 | 51 | 51 |
| EBITDA | 1 | −4 | 6 | −65 | −5 | −9 | −5 | −6 | −12 | −10 | −7 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 1 | −4 | 6 | −65 | −5 | −9 | −5 | −6 | −12 | −10 | −7 | −3 |